Katsuyuki Kiura

Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial

Alice T. Shaw, Tae Min Kim, Lucio Crinò et al. · The Lancet Oncology · 2017 · 580 citations · Full text

Medicine, Oncology, Pharmacology +12

CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study

Takashi Seto, Katsuyuki Kiura, Makoto Nishio et al. · The Lancet Oncology · 2013 · 576 citations

Medicine, Oncology, Pharmacology +11

The Relationship between Epidermal Growth Factor Receptor Mutations and Clinicopathologic Features in Non–Small Cell Lung Cancers

Masaki Tokumo, Shinichi Toyooka, Katsuyuki Kiura et al. · Clinical Cancer Research · 2005 · 496 citations · Full text

Medicine, Genetics, Oncology +15

Presence of<i>Epidermal Growth Factor Receptor</i>Gene T790M Mutation as a Minor Clone in Non–Small Cell Lung Cancer

Michio Inukai, Shinichi Toyooka, Sachio Ito et al. · Cancer Research · 2006 · 447 citations · Full text

Medicine, Oncology, Pharmacology +13

Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor <i>BRAF</i> gene mutations but lack mutations in <i>KRAS, NRAS,</i> or <i>MEK1</i>

Kadoaki Ohashi, Lecia V. Sequist, Maria E. Arcila et al. · Proceedings of the National Academy of Sciences · 2012 · 437 citations · Full text

Medicine, Molecular Biology, Oncology +17